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Detecting antibiotic resistance in Mycobacterium tuberculosis is becoming increasingly important with the
global recognition of drug-resistant strains and their adverse impact on clinical outcomes. Current methods of
susceptibility testing are either time-consuming or costly; rapid, reliable, simple, and inexpensive methods
would be highly desirable, especially in the developing world where most tuberculosis is found. The luciferase
reporter phage is a unique reagent well-suited for this purpose: upon infection with viable mycobacteria, it
produces quantifiable light which is not observed in mycobacterial cells treated with active antimicrobials. In
this report, we describe a modification of our original assay, which allows detection of the emitted light with
a Polaroid film box designated the Bronx Box. The technique has been applied to 25 M. tuberculosis reference
and clinical strains, and criteria are presented which allow rapid and simple discrimination among strains
susceptible or resistant to isoniazid and rifampin, the major antituberculosis agents.
A recent World Health Organization (WHO) study docu-
ments that drug-resistant tuberculosis (TB) is now a worldwide
phenomenon (23, 41). Since multiply drug-resistant TB is dif-
ficult to eradicate with the WHO-recommended short-course
treatment regimens (12, 23, 41), its presence complicates ef-
forts to reduce the estimated 8 million new cases and prevent
the 3 million deaths from TB predicted to occur each year (28).
Inappropriate therapy of drug-resistant Mycobacterium tuber-
culosis may lead to increased levels of resistance to multiple
drugs (17), increased costs for retreatment regimens (17), in-
creased opportunities for spread to contacts and health care
workers (9, 19, 26), and increased mortality (24, 37). Nonethe-
less, early recognition of drug-resistant M. tuberculosis can lead
to effective interventions, even in those who are human immu-
nodeficiency virus (HIV) infected (37). Accordingly, the Cen-
ters for Disease Control and Prevention (CDC) have recom-
mended that the detection of drug-resistant M. tuberculosis,
and institution of appropriate therapy, be expedited (6).
However, practical antibiotic susceptibility testing (AST) of
M. tuberculosis remains problematic, especially in the develop-
ing world. Conventional methods such as the agar-based pro-
portion technique require 3 to 6 weeks for results, while the
BACTEC radiometric method requires only 1 to 2 weeks but
utilizes radioactive substrates and expensive technology (11).
Similar time-to-results as that for the BACTEC method have
been reported for E-test (38) and redox-indicator-dye methods
(42). Novel methods for AST such as genotypic assays (20, 36)
and flow cytometry (15) are more rapid, requiring 1 to 2 days,
but are technology intensive. Finally, relatively rapid assess-
ments of mycobacterial viability (in the presence of effective
antibiotics) have been performed by quantifying mycobacterial
ATP stores (22) or by measuring the ability of viable mycobac-
teria to support bacteriophage replication (39) or to synthesize
the sensitive reporter gene product, firefly luciferase (2, 7).
We have developed a method which combines elements of
these phenotypic assays, utilizing bacteriophage to introduce
the firefly luciferase gene (Fflux) into any viable isolate of
M. tuberculosis, thus yielding visible light in the presence of
cellular ATP and the exogenous substrate luciferin (5, 14, 29).
Effective antimycobacterial drugs will abrogate light produc-
tion in this system either by decreasing ATP stores, by impair-
ing luciferase protein production, or by interfering with pro-
ductive phage infection; AST can be performed within 2 to 3
days (5, 14, 29). The greatest cost issue with this method is the
requirement for a luminometer to quantify the light output.
Alternative methods for detecting luciferase activity have been
described, i.e., using X-ray film for colonies of transformed
Escherichia coli (40) or Candida albicans (34) and polaroid film
for recombinant HIV-infected (13) or pseudorabies (16) virus-
infected mammalian cells. Film has also been used to detect
nontuberculous mycobacterial strains constitutively expressing
luciferase after infection with a lysogenic recombinant phage
(31). In the present work, we describe conditions for photo-
graphic detection of light from recombinant lytic phage-in-
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fected M. tuberculosis by using a custom-made light-tight box
which accommodates a 96-well plate and a polaroid film cas-
sette and their application for rapid AST of clinical M. tuber-
culosis isolates.
MATERIALS AND METHODS
Mycobacteria. BCG-Pasteur (ATCC 35734), M. tuberculosis Erdman (ATCC
35801), Mycobacterium smegmatis mc2155 (33), and spontaneous drug-resistant
mutants of M. smegmatis—mc217 (rifampin resistant) (unpublished), mc2651
(isoniazid [INH]-resistant) (3), and mc21255 (streptomycin resistant) (25)—are from
our reference collection. BCG::FFlux is BCG-Pasteur transformed with pKB15,
an integrating plasmid which leads to expression of Fflux from the PL promoter
of phage L5 (21). All other clinical strains were obtained from the clinical
mycobacteriology laboratories of the Montefiore Medical Center of the Albert
Einstein College of Medicine, Bronx, N.Y. (n 5 17) or the Kings County Hos-
pital Center, Brooklyn, N.Y. (n 5 6). These clinical strains can be subdivided into
(i) reference strains submitted for proficiency testing (date of submission in
brackets) by the CDC (n 5 5, strains A and B [Feb. 1998], I [Aug. 1996], K [Jan.
1996], and S [June 1997]) or by the College of American Pathologists (n 5 1,
strain E05 [1997]), with well-validated AST results, and (ii) primary clinical
isolates (n 5 17) obtained by the participating hospitals. AST was performed for
the clinical isolates by the BACTEC 460 method, and if resistance was found, it
was confirmed by the agar-proportion method (11). Mycobacteria were grown in
Middlebrook 7H9 medium (Difco, Detroit, Mich.) supplemented with 0.5%
bovine serum albumin, fraction V (Boehringer Mannheim, Indianapolis, Ind.),
0.9% NaCl, 0.2% glycerol, and 0.2% glucose (MADC) and was further supple-
mented with 0.05% Tween-80. BCG::Fflux was grown in MADC with Tween and
50 mg of hygromycin/ml. Reagents were obtained from Sigma Chemical Co., St.
Louis, Mo.
Luciferase reporter phage. Luciferase reporter phage phAE85, constructed as
described by Carrie`re et al. (5), was utilized for these experiments. It was prop-
agated on lawns of M. smegmatis mc2155, as mentioned previously, and was
maintained at a titer of .1011 PFU/ml in SM buffer (0.58% NaCl, 0.2% MgSO4,
0.01% gelatin, 50 mM Tris [pH 7.5]).
The Bronx Box. This is a custom-made light-tight aluminum box manufactured
by one of us (L.F.) which accommodates a Microlite 1 96-well plate (Dynex,
Chantilly, Va.) and a Polaroid 545 Land Film Holder cassette loaded with
Polapan 57 3000 ASA film (Polaroid, Cambridge, Mass.) (Fig. 1a). This device
can be placed within a zippered black pouch with sleeves and armholes for
loading and removing the film in complete darkness; alternatively, the box can be
sealed with regular opaque laboratory tape or placed within a drawer during
development. These steps are not essential but result in sharper pictures.
Antibiotics. INH, rifampin, streptomycin, and ethambutol (all from Sigma)
were diluted in water (or methanol for rifampin), and then filtered and diluted
in sterile distilled water to a 103 working concentration as follows: INH, 1 or 2
mg/ml; rifampin, 20 mg/ml; streptomycin, 20 mg/ml; ethambutol, 75 mg/ml.
Luciferin buffer evaluation. The optimized luciferin buffer (“flash luciferin”)
for luminometer readings from luciferase-expressing mycobacteria was previ-
ously shown to consist of 50 mM sodium citrate (SC) (pH 4.5) with 0.33 mM
luciferin (modified from reference 14). In this work, we developed an optimized
“glow luciferin” buffer for photographic detection, consisting of 50 mM SC (pH
5.3), 8 mM dithiothreitol (DTT), and 12 mM MgSO4 (stored at 4°C up to 1 week)
supplemented with 0.2 mM luciferin (adjusted to pH 5 to 6, stored at 220°C, and
freshly thawed before use). All reagents were obtained from Sigma. All buffers
were initially evaluated by using 10 ml of BCG::Fflux with 100 ml of each buffer
loaded into wells of a Microlite 1 plate (Dynex) and assayed on a Dynatech
ML3000 luminometer (Dynex) (cycle mode, 10 s reading every 15 s).
AST testing (liquid media). A smooth liquid culture of mycobacteria was
obtained after cultivation in MADC with Tween for 5 to 21 days until a turbidity
of at least 2 McFarland units (corresponding to .5 3 107 CFU/ml) (Remel,
Lenexa, Kan.) was attained. Since Tween interferes with phage infection (14, 29),
1 to 2 ml of cells were centrifuged twice (1,800 3 g, 15 min, 20°C) with 5 ml of
wash medium (MADC with 1% glycerol) and resuspended in the original volume
of MADC without Tween. Then, 180 ml of the washed mycobacteria was added
to separate wells of a sterile Microlite 1 plate containing 20 ml of MADC or 103
concentrations of INH and rifampin, and in certain experiments streptomycin
and ethambutol. The plate was covered with a lid, sealed with Parafilm, and
incubated for 48 h at 37°C. Then, 20 ml of phage was added to each well, and
after 4 to 6 h at 37°C, duplicate 25-ml aliquots from each well were removed for
quantitative luciferase assays on a LUMAC 2010a luminometer (Celsis, Mon-
mouth Park, N.J.). A total of 100 ml of flash luciferin buffer was injected, and the
relative light units (rlu) were measured after 10 s of integration. An inhibition
index for each antibiotic was calculated as [(rlu after antibiotic treatment)/(rlu
without antibiotics)] 3 100, an index of ,10% has been found to correlate with
a strain being susceptible, while an index of .10% is considered resistant (29,
30). For the Bronx Box experiments, 100 ml of glow luciferin buffer was added to
125 ml of phage-infected mycobacteria (with or without antibiotics) in each of the
wells of the Microlite 1 plate. The plate was covered with an acetate plate sealing
membrane (no. 3501; Dynex) and loaded into the chamber of the Bronx Box,
superimposed with Polaroid Polapan 57 film in its cassette. After a 3-h or over-
night (16 h) exposure, the film was developed and spots of light were visualized.
Direct AST testing from solid media. Some mycobacteria were derived directly
from Lo¨wenstein-Jensen slants (BBL, Cockeysville, Md.) or Middlebrook 7H10
agar (Difco) plates supplemented with oleic acid albumin dextrose complex
(BBL). Several colonies were scraped and transferred to a 15-ml polystyrene
centrifuge tube containing sterile 4-mm-diameter glass beads (Fisher Scientific,
Pittsburgh, Pa.) and 1.5 ml of MADC. After vortexing for 20 s, any large clumps
of cells remaining were allowed to settle for 10 min, and 1 ml of the supernatant
(approximate turbidity of 2 McFarland units) was directly utilized for AST
assays, as described above, without the need for washing. Notably, the 103
concentration of INH was reduced to 1 mg/ml, and the duration of antibiotic
action was extended to 72 h.
RESULTS
The Bronx Box assay can assess drug susceptibilities of
mycobacteria. The ability of the Bronx Box assay to detect light
from luciferase reporter phage-infected mycobacteria was first
evaluated with the nonpathogenic rapid-growing mycobacte-
FIG. 1. (a) Picture of the Bronx Box. (b) Result of a Bronx Box AST experiment with M. smegmatis strains mc2155 (fully susceptible), mc2651 (INH resistant), mc217
(rifampin resistant), and mc21255 (streptomycin resistant). Each strain (200 ml of a culture grown to an optical density at 600 nm of 0.5) was treated with medium alone
(no antibiotic) or antibiotics (rifampin, 100 mg/ml; INH, 25 mg/ml; streptomycin, 100 mg/ml) for 12 h. A total of 20 ml of phAE85 was added to each sample, and after
a further 6-h incubation, 100 ml of flash luciferin buffer was added and the plate was loaded in the Bronx Box for a 12-h exposure. Spots of light correspond to wells
containing viable mycobacteria.
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rium M. smegmatis and phAE85. Further, the availability of
known drug-resistant mutant strains of M. smegmatis allowed
us to test whether the Bronx Box assay could be used to reliably
identify the presence of drug resistance. In fact, with minimal
modification of our prior luminometer-based protocols (14,
29), with our flash luciferin buffer, clearly visible spots were ob-
tained from wells containing each of the M. smegmatis strains
infected with phAE85 (Fig. 1b). In addition, spots of equiva-
lent intensity were seen from each of the drug-resistant strains
in the presence of the antibiotic to which they were resistant;
no spots were seen in wells containing a mycobacterium treat-
ed with an antibiotic to which it was susceptible (Fig. 1b). In
these assays, approximately 2 3 107 CFU of mycobacteria were
utilized per assay. In adapting this protocol to the slower-grow-
ing, pathogenic mycobacteria, and to improve our sensitivity of
detection, several further modifications were considered.
Optimization of luciferin buffer. Preliminary experiments
with our luminometer-optimized reporter phage assays showed
that after addition of the luciferin substrate, the light output
peaked rapidly, within seconds, and then declined to a new base-
line of only 10 to 25% of the peak which then decayed more
gradually (see Fig. 2, SC 4.5). It was apparent that a photo-
graphic detection method with this type of buffer would be un-
able to measure the peak due to the manipulation time re-
quired for loading the film. Therefore, a method was sought for
either (i) predictably delaying the onset of the peak, (ii) elevat-
ing the level of the “steady-state” baseline light output value,
or optimally (iii) doing both in extending the duration of the
peak beyond the initial seconds. There is evidence from cell-
free luciferase readout systems that extended light output can
be achieved by modifications of the reaction buffer (1, 18), so
we assessed these methods in our in vivo mycobacterial cell
assay.
First, we confirmed preliminary work which identified a pH
of 4.5 as optimal for luminometer-based detection, and then
we measured the light output over a 1- to 2-h period rather
than just over the first few seconds. The low pH apparently
stabilizes the luciferin substrate and allows it to enter the
mycobacterial cell in its uncharged form (1). However, a higher
pH might (i) allow the photon generation to occur closer to its
most efficient pH (i.e., 8 to 9) (1) and (ii) preserve mycobac-
terial cell viability (8), enhancing the duration of light output,
even though the luciferin would be less readily available intra-
cellularly. We used a strain of BCG constitutively expressing
firefly luciferase (BCG::Fflux) as the source of intracellular
luciferase for these experiments and fixed the luciferin concen-
tration at 0.2 mM. As previously seen, peak light output de-
creased with a rising pH above pH 4.5 with the following
buffer: 50 mM SC at pH 4.1, 4.6, 5.3, and 6; 25 mM HEPES at
pH 6.4, 7.2, and 8; 50 mM Gly-gly at pH 7.8, and 50 mM Tris
at pH 7.0 and 7.8. Nonetheless, this work confirmed that at a
higher pH, light output was generated, though of lower ampli-
tude and at a significantly delayed onset (data not shown). We
therefore sought to boost this delayed peak by adding other
previously described modifiers of the luciferase reaction, Mg,
DTT, and ATP (1, 18), to the pH 7.8 buffered luciferin solu-
tion. The results in Fig. 2 show that this approach is successful,
with each of these components required for extending the light
output and increasing its amplitude. Next, we considered the
effects of these reagents on the lower pH buffer systems. Sur-
prisingly, while ATP was beneficial with Tris buffer at pH 7.8,
it actually interfered with optimal light output if added to ei-
ther HEPES buffer (pH 6.4) (not shown) or SC buffer (pH 5.3)
(Fig. 2).
Testing of luciferin buffers in the Bronx Box. The best buff-
ers from the experiments described above were compared to
the standard flash luciferin in the Bronx Box with dilutions of
BCG::Fflux as the source of luciferase. After a 3-h exposure of
film, the brightest spots and the highest sensitivities were ob-
tained with either SC buffer at pH 5.3 with DTT and Mg or
with Tris at pH 7.8 containing DTT, Mg, and ATP. Notably, a
further overnight exposure (reloading the Bronx Box after the
first 3 h) showed residual spots, albeit much lighter than on the
3-h film, suggesting that not all of the emitted light is exhausted
in the first 3 h and that for optimal sensitivity, overnight ex-
posure should be used. In all further experiments, the SC pH
5.3 buffer with DTT and Mg was utilized (and designated glow
luciferin buffer) inasmuch as the Tris buffer (with ATP) re-
quired an additional and labile component, the ATP, which
might potentially confound our AST assays. The superior sen-
sitivity of the glow luciferin buffer to the flash luciferin was also
confirmed using Erdman and BCG mycobacteria infected with
phAE85 for 3 h and then treated with the respective buffers.
Finally, certain other conditions were tested for their effect
on light output directly in the Bronx Box with BCG::Fflux.
The roles of supplemental calcium (1 to 10 mM) (10, 18),
pyrophosphate (1 to 100 mM) (18), and a range of luciferin
concentrations (0.1 to 1 mM) were evaluated, showing nonsig-
nificant differences from the above-noted optimized glow lu-
ciferin buffer.
Adapting the Bronx Box assay for M. tuberculosis. In order to
work with M. tuberculosis, a biosafety level 3 pathogen, a mod-
ification of the Bronx Box protocol was required, either the
film box had to be entirely contained within a biosafety hood or
the plate containing the mycobacteria had to be sealed before
being removed from the hood. Given that the latter was more
practical, the oxygen requirement of the reaction had to be
considered. Therefore, an O2-permeable transparent acetate seal-
ing membrane (Dynex no. 3501) was adhered over the plate prior
to loading in the Bronx Box. There was no attenuation of the
FIG. 2. Kinetics of luciferase-generated light production depends on the
composition of luciferin buffer. A total of 10 ml of BCG::Fflux (constitutively
expressing luciferase) was treated with 90 ml of 0.2 mM luciferin in the following
buffers (from top to bottom in the figure): 15 mM Tris (pH 7.8) with 12.5 mM
DTT–15 mM MgSO4–6 mM ATP, 50 mM SC (pH 5.3) with 12.5 mM DTT–15
mM MgSO4, 50 mM SC (pH 5.3) with 12.5 mM DTT–15 mM MgSO4–6 mM
ATP, 15 mM Tris (pH 7.8) with 12.5 mM DTT–15 mM MgSO4, and 50 mM SC
(pH 4.5). Photons (rlu) were measured every 15 s for 2 h with a Dynatech
ML3000 luminometer (cycle mode).
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light signal when identical wells containing the nonpathogen
BCG::Fflux were tested with or without the membrane (Fig. 3).
Sensitivity of detection with the Bronx Box assay. With our
luminometer, the threshold of detection for obtaining obvious
spots is about 2,000 rlu per 25 ml of cells when 125 ml of cells
is utilized for the Bronx Box assay (e.g., Fig. 3). Further, there
is a linear correlation between the intensity of the spots and the
rlu readings obtained by a luminometer. In order to establish
the minimum number of cells required to produce a spot on
the Polaroid film in the Bronx Box assay, we tested serial two-
fold dilutions of BCG-Pasteur and M. tuberculosis Erdman
infected with phAE85. After 6 h of phage infection, glow lu-
ciferin buffer was added, and the film was exposed for an
additional 3 h or overnight. A 16-fold dilution of each of the
strains was visualized as a spot at 3 h, corresponding to 1.7 3
106 CFU of each mycobacterium. The sensitivity of the assay
for detecting BCG::Fflux is 20-fold greater (Fig. 3), reflecting
the fact that each cell in this population constitutively and
synchronously expressed high levels of luciferase. In order to
further boost the sensitivity, 20,000 ASA Polaroid film was test-
ed; surprisingly, it produced no greater sensitivity of detection,
perhaps because the spectral frequency of the emitted light was
not able to be optimally detected by this film.
Applying the Bronx Box assay for AST of M. tuberculosis. In
preliminary experiments using the non-pathogens M. smegma-
tis (Fig. 1b) and M. bovis BCG (not shown), the presence of
spots after phage infection in the Bronx Box assay could be
abolished by 1 to 2 days of pretreatment with effective antibi-
otics (INH, rifampin, or streptomycin). This effect correspond-
ed to a decrease of .90% in the emitted light (rlu) in these
antibiotic-containing wells, as measured by a luminometer. We
then extended these assays to clinical strains of M. tuberculosis
with various antibiotic susceptibilities. Although a range of an-
tibiotic concentrations can be readily tested in this system, we
chose those breakpoint concentrations which were previously
shown to be useful in discriminating susceptible from resistant
organisms in this (5, 29, 30) and similar systems (2, 8). Of note,
the concentration of INH was increased from 0.1 to 0.2 mg/ml
to account for the larger inoculum of cells being used than in
our prior studies. A typical result with four different strains is
shown in Fig. 4. In total, 25 unique strains were tested in 58
experiments and produced spots after phAE85 infection. The
AST results with these strains are summarized in Table 1,
showing that the accuracy of the assay for INH and rifampin,
the major anti-tuberculosis agents, was nearly 100%. The one
exception was a strain from a patient who relapsed after pro-
longed therapy with rifampin, ethambutol, and ofloxacin. The
relapse isolate was identified as being rifampin susceptible by
the BACTEC method but was repeatedly identified as being
rifampin resistant by the Bronx Box assay. Molecular analysis
of a subsequent isolate from the same patient (30a) revealed a
genotypic correlate of rifampin resistance (an amino acid 533
Leu to Pro mutation) which has been associated previously
with phenotypic resistance (35). Thus, there is both clinical and
genotypic (by sequencing) evidence that corroborates the phe-
notypic resistance suggested for this strain by the Bronx Box
assay.
Bronx Box assay for direct AST from agar. Although the
strains tested as described above were derived from broth cul-
tures at a density of 2 McFarland units, a more direct approach
was evaluated whereby freshly growing tuberculous strains on
Lo¨wenstein-Jensen or 7H10 slants were inoculated into media
to produce a 2 McFarland unit suspension and distributed
immediately for AST experiments. Two modifications of the
liquid protocol were found to be useful: (i) 3 days of incubation
rather than 2 days was optimal to allow full antibiotic efficacy,
and (ii) the INH concentration could be reduced to the more
standard 0.1 mg/ml. Phage was added and antibiotic suscep-
tibility measured as before with the Bronx Box assay. Once
again, spots were observed in the no antibiotic well and in wells
containing antibiotic to which the organism was found to be
resistant but were not observed in wells containing effective
antibiotics. The results for nine strains tested with the above
protocol are summarized in Table 1. Four strains were primary
FIG. 3. Sensitivity of detection of luciferase in the Bronx Box with (1) and
without (2) acetate membrane covering. A twofold dilution series, starting from
a 1 to 10 dilution of a 2 McFarland unit culture of BCG::Fflux (100 ml in each of
6 wells, from approximately 2 3 106 (left) to 0.7 3 105 CFU (right) were each
treated with 100 ml of glow luciferin buffer (see text), loaded in the Bronx Box,
and exposed for 3 h.
FIG. 4. Bronx Box AST of clinical M. tuberculosis strains. A total of 125 ml of
mycobacteria was treated with medium alone (1) or with INH (0.2 mg/ml) (H),
rifampin (2 mg/ml) (R), or ethambutol (2.5 mg/ml) (E) for 48 h. The mycobac-
teria were then treated with 100 ml of glow luciferin buffer, loaded in the Bronx
Box, and exposed for 3 h. The mycobacteria tested were the Erdman susceptible
reference strain (ERD), a CDC INH-resistant strain (CDC-K), and clinical mono-
resistant (Z) and multidrug resistant (DS) strains.
TABLE 1. Sensitivity and specificity of the Bronx Box assay for
detecting antibiotic resistance in unique M. tuberculosis isolates
Growth
platform
INH Rifampin
%
Sensitivitya
%
Specificityb
%
Sensitivitya
%
Specificityb
Liquid medium 100 (8/8) 100 (13/13) 100 (8/8) 93 (14/15)
Solid medium 100 (3/3) 100 (6/6) 100 (3/3) 100 (6/6)
Either mediumc 100 (9/9) 100 (16/16) 100 (10/10) 94 (16/17)
a Values in parentheses are number of resistant strains correctly identified/
number of resistant strains tested.
b Values in parentheses are number of susceptible strains correctly identified/
number of susceptible strains tested.
c Some strains were tested on both media.
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clinical isolates grown on Lo¨wenstein-Jensen slants, while the
other five strains were previously tested and were grown on
Middlebrook 7H10 plates. Concordance with the expected sus-
ceptibilities was 100% for these strains for INH and rifampin
(Table 1).
DISCUSSION
The WHO states that TB control is lacking precisely in
countries where the disease is most prevalent (41). The pres-
ence of TB, and especially drug-resistant TB, in these devel-
oping nations is a concern for all, since we are in an era of
global commerce and migrations. In the United States, for ex-
ample, a major contributor to the rise in TB cases in the 1990s
has been the influx of foreign-born cases (4). Thus attention to
TB control throughout the world should be a priority for the
developed world as much as for the developing world.
Part of the problem in TB control in developing nations is
inadequate resources to perform drug susceptibility test and
ensure appropriate therapy for all patients. We have previously
shown that the luciferase reporter phage assay is useful for de-
termining antibiotic susceptibilities of clinical strains of M. tu-
berculosis, with sensitivity (5) and specificity (28), in a timely
and a relatively “low-tech” manner. To further expedite the
use of this assay in developing countries where most tubercu-
losis occurs, we have developed a photographic detection ap-
paratus, designated the Bronx Box, which greatly simplifies the
detection protocol and removes the requirement for the most
costly component in the protocol, a luminometer. The semi-
quantitative output which results is simple to interpret and ac-
curate compared to that from the luminometer or conventional
AST assays. Furthermore, we show here that our method can
be applied directly to primary isolates of M. tuberculosis grown
on solid agar, available in 3 to 4 weeks from the time of sample
acquisition (11) and still the most common means of cultivat-
ing M. tuberculosis worldwide (23, 41).
Significantly, our method uses concentrations of antibiotics
which have been validated in the other major liquid AST meth-
odology, the BACTEC method (32). We are thus able to cor-
rectly identify even low-level resistant strains (some of the
MICs for the reference strains are close to the breakpoint) and
in the case of the one rifampin-resistant “misdiagnosis,” may
actually be more sensitive for early emergence of resistance. In
fact, if the assay is applied earlier to primary cultures, slower-
growing resistant subpopulations could be detected more read-
ily than by other growth-based methods. Furthermore, subtle
differences from wild-type patterns of susceptibility can be eval-
uated by applying a range of antibiotic concentrations in cal-
culating an MIC (42). Though not common in our data set, the
issue of intermediate susceptibility needs to be considered,
whether for a heterogeneous population of strains or for a
homogeneous population which has a slightly elevated MIC
relative to that for wild-type isolates. We have observed that
phage-induced light production (measured by a luminometer)
is reduced by at least 90% after antibiotic treatment of strains
considered to be susceptible by conventional assays (29). Con-
versely, resistant strains in the presence of ineffective antibiot-
ics produce at least 10% of the light observed without any
antibiotic (29). In order to be certain that this 10% threshold
can be visualized by the Bronx Box assay, we are currently in-
cluding an additional control, a 1:10 dilution of the no-antibi-
otic, phage-infected cells. If this well produces any spot at all,
we are confident that we will be able to visualize any relevant
resistance, should it be present, as spots of similar or greater
intensity in the antibiotic-containing wells.
While not reported here, other antimycobacterial agents can
be tested or screened for activity by using photographic detec-
tion. Our preliminary data with ethambutol and streptomycin
in this data set, while still being optimized, reveal a sensitivity
and specificity of 50 and 97% for ethambutol resistance and 89
and 67% for streptomycin resistance, respectively. Notably these
antibiotics have been difficult to standardize for AST (41) and
have undergone modification of their breakpoints even with
conventional methods (32).
Our efforts to improve the sensitivity of photographic detec-
tion were largely empirical. Though it is not clear why DTT
and Mg affect the kinetics of luciferase-generated light output,
it can be postulated that the DTT stabilizes the luciferin and
Mg stabilizes the ATP (18). Although it has been shown that
high ATP levels can interfere with light production (1), it is still
surprising that at low pH, modest levels of extrinsic ATP can
dampen light production in our in vivo luciferase detection
system. Understanding these phenomena may help guide us
in developing superior reaction conditions. In the meantime,
there are ongoing efforts in our laboratory to improve the sen-
sitivity of the film detection system by using more sophisticated
optics and newer phages. In addition, we hope to further sim-
plify the protocol (i) to be able to add phage and luciferin at
the same time and (ii) to be able to add phage and antibiotics
at the same time, with a lysogenic phage (10, 31). We plan to ex-
tend the methods directly to processed sputum samples. Final-
ly, we aim to verify that a phage-infected mycobacterial culture
is far less virulent than an uninfected culture, given that excess
phage in the assay ultimately will lyse all the mycobacterial cells,
thus providing an important extra measure of laboratory safety.
In summary, the Bronx Box adaptation of the luciferase re-
porter phage assay is a rapid, reliable means for performing
antibiotic susceptibility testing of cultures M. tuberculosis in a
simple, low-tech manner well-suited to the challenge of drug-
resistant TB in the developing world. While further validation
of the method is necessary, clinical trials in TB-ravaged coun-
tries are currently being initiated.
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